교원정보

학술지 논문

• (2023)  Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.  CLINICAL CANCER RESEARCH.  23,  1689
• (2023)  Dosimetric comparison between RapidArc and HyperArc in hippocampal-sparing whole-brain radiotherapy with a simultaneous integrated boost.  MEDICAL DOSIMETRY.  x,  x
• (2023)  Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer.  JOURNAL OF CLINICAL MEDICINE.  12,  9
• (2023)  Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.  24,  8
• (2023)  A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.  CANCER RESEARCH AND TREATMENT.  55,  4
• (2022)  Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.  CANCERS.  14,  14
• (2022)  Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.  JTO Clinical and Research Reports.  3,  6
• (2022)  Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.  CANCERS.  14,  8
• (2022)  Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.  ESMO OPEN.  7,  2
• (2022)  Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial.  JOURNAL OF CANCER.  13,  3
• (2021)  Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.  CLINICAL CANCER RESEARCH.  27,  19
• (2021)  Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).  EUROPEAN JOURNAL OF CANCER.  157,  2021
• (2021)  Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.  THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.  13,  1
• (2021)  A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin postoperative chemoradiation with S-1 oxaliplatin in patients with node-positive gastric cancer after D2 resection the ARTIST 2 trial.  ANNALS OF ONCOLOGY.  32,  3
• (2021)  Relationship between heavy metal exposure and type 2 diabetes: a large-scale retrospective cohort study using occupational health examinations.  BMJ OPEN.  11,  3
• (2021)  Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.  LANCET ONCOLOGY.  22,  1
• (2020)  Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.  LUNG CANCER.  149,  1
• (2020)  rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects.  CANCERS.  12,  11
• (2020)  A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.  ONCOLOGIST.  25,  1
• (2019)  Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.  LANCET.  394,  10212